NextPlat Corp Dossier - Source-backed chat

NextPlat Corp

NXPLNASDAQ

SectorConsumer Staples

IndustryDrug Retail

Beta (adjusted)1.58

Intrinsic Value $15.20median of 2 methodsbased on filings through 30 Jun 2026

Market Price $8.71Price as of 1 Oct 2026

Significantly undervaluedIntrinsic value is 75% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (+75%)

Data confidence Sign in to view data confidence

Market Cap $23.6M

Enterprise Value $12.7M

Shares Outstanding 2.7M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

NextPlat Corp is navigating a critical operational turnaround, shifting its focus toward higher-margin contracted healthcare services and expanding its e-commerce footprint. While the company achieved a record consolidated gross margin of 35% in Q1 2026 and significantly reduced its operating expenses, it remains loss-making with a net loss of $1.1 million for the quarter. The launch of its 50-state nationwide medication fulfillment capabilities in collaboration with HealthWarehouse.com represents a major growth catalyst. However, a substantial supply overhang from the registration of 2,097,011 shares for resale by selling securityholders (representing a significant portion of the 2,708,507 outstanding shares) and historical execution risks warrant a cautious Hold recommendation until consistent profitability is demonstrated.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$12.00

Mean target$12.00

High · most bullish analyst$12.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The resale of registered shares by selling securityholders creates severe downward pressure on the stock price. Turnaround initiatives in the healthcare segment stall due to regulatory hurdles or intense competition, delaying the path to positive operating income and depleting cash reserves.

Base CaseCentral scenario

The company successfully leverages its HealthWarehouse partnership to expand healthcare revenues outside of Florida, maintaining gross margins above 30% and achieving positive operating income in the second half of 2026 as guided by management. Prudent expense controls continue to narrow net losses.

Bull CaseUpside scenario

NextPlat's bull case is driven by the strategic expansion of its healthcare segment, specifically shifting focus from low-margin retail pharmacy services to higher-margin contracted services for 340B entities and long-term care facilities. This transition is supported by an aging population driving medication demand and a shrinking footprint of large retail pharmacy chains. Additionally, the company is expanding its geographic reach beyond Florida through nationwide online fulfillment partnerships and is experiencing growing demand for satellite communications within its e-commerce segment. These operational shifts have already begun to yield measurable financial improvements, including record gross margins and reduced operating losses.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Record consolidated gross margins of 35% in Q1 2026, up from 21% in the prior year period, driven by higher-margin contracted services and improved drug costing.
Strategic 50-state nationwide medication fulfillment partnership with HealthWarehouse.com, significantly expanding the addressable market beyond Florida.
Solid balance sheet with approximately $11 million in cash, $14.2 million in working capital, and zero unsecured debt as of March 31, 2026.

Key Investment Risks

Significant supply overhang from the registration of 2,097,011 shares for resale, which is highly material relative to the 2,708,507 shares outstanding.
History of persistent net losses, including a net loss of $10.5 million in 2025 and $22.5 million in 2024, resulting in an accumulated deficit of $61.2 million as of March 31, 2026.
High concentration risk, including reliance on Amazon for approximately 31% of e-commerce revenue and McKesson for 98% of pharmaceutical purchases in 2025.

Thesis Invalidation Triggers

Failure to achieve positive operating income in the second half of 2026.
A severe drop in cash balances below $5 million, indicating a faster-than-expected burn rate.
Termination or material negative modification of the HealthWarehouse partnership or key 340B contracts.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.